Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PHVS Pharvaris	$22.30 -3.0%	$19.71	$11.51 ▼ $26.33	$1.17B	-2.81	192,452 shs	167,398 shs
RCUS Arcus Biosciences	$10.39 +4.8%	$9.17	$6.50 ▼ $18.98	$1.11B	0.89	783,392 shs	883,218 shs
SYRE Spyre Therapeutics	$16.95 +0.5%	$16.26	$10.91 ▼ $40.26	$1.02B	2.82	505,881 shs	536,949 shs
TKNO Alpha Teknova	$4.69 -2.3%	$4.96	$3.90 ▼ $10.37	$250.99M	0.32	332,291 shs	124,902 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PHVS Pharvaris	0.00%	+10.83%	-6.03%	+34.66%	+31.95%
RCUS Arcus Biosciences	0.00%	+14.36%	+10.04%	+21.38%	-28.98%
SYRE Spyre Therapeutics	0.00%	+11.81%	+0.36%	+11.66%	-31.46%
TKNO Alpha Teknova	0.00%	+10.87%	+7.57%	-29.05%	+26.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PHVS Pharvaris	2.4464 of 5 stars	3.5	4.0	2.4	0.8	0.0
RCUS Arcus Biosciences	2.0631 of 5 stars	3.4	3.0	1.7	1.7	0.0
SYRE Spyre Therapeutics	3.1265 of 5 stars	3.6	2.0	3.6	2.5	0.6
TKNO Alpha Teknova	2.3796 of 5 stars	3.8	1.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PHVS Pharvaris	3.00	Buy	$35.60	59.64% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	103.49% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	215.04% Upside
TKNO Alpha Teknova	3.50	Strong Buy	$10.00	113.22% Upside

Current Analyst Ratings Breakdown

Latest TKNO, RCUS, PHVS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
7/22/2025	TKNO Alpha Teknova	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.00 per share	N/A
RCUS Arcus Biosciences	$258M	4.29	N/A	N/A	$5.16 per share	2.01
SYRE Spyre Therapeutics	$890K	1,150.31	N/A	N/A	$4.97 per share	3.41
TKNO Alpha Teknova	$38.92M	6.45	N/A	N/A	$1.42 per share	3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PHVS Pharvaris	-$145.24M	-$3.36	N/A	N/A	N/A	N/A	-69.09%	-63.34%	N/A
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	N/A
TKNO Alpha Teknova	-$26.75M	-$0.42	N/A	N/A	N/A	-55.24%	-26.51%	-18.40%	N/A

Latest TKNO, RCUS, PHVS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2025	PHVS Pharvaris	-$0.87	-$0.94	-$0.07	-$0.94	N/A	N/A
8/7/2025	Q2 2025	TKNO Alpha Teknova	-$0.1004	-$0.07	+$0.0304	-$0.07	$9.90 million	$10.29 million
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PHVS Pharvaris	N/A	8.33	11.10
RCUS Arcus Biosciences	0.18	4.50	4.50
SYRE Spyre Therapeutics	N/A	6.49	6.49
TKNO Alpha Teknova	0.17	5.87	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PHVS Pharvaris	N/A
RCUS Arcus Biosciences	92.89%
SYRE Spyre Therapeutics	80.39%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
PHVS Pharvaris	11.84%
RCUS Arcus Biosciences	9.60%
SYRE Spyre Therapeutics	15.43%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable
TKNO Alpha Teknova	240	53.52 million	46.83 million	Not Optionable

TKNO, RCUS, PHVS, and SYRE Headlines

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results

August 11, 2025 | marketbeat.com

Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

August 8, 2025 | aol.comA

CenterBook Partners LP Takes Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

August 8, 2025 | marketbeat.com

Teknova Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Holdings Lifted by Mount Lucas Management LP

July 24, 2025 | marketbeat.com

Alpha Teknova (NASDAQ:TKNO) Earns Overweight Rating from Analysts at Stephens

July 22, 2025 | marketbeat.com

Pleasing Signs As A Number Of Insiders Buy Alpha Teknova Stock

July 9, 2025 | finance.yahoo.com

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2, 2025 | insidertrades.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO, RCUS, PHVS, and SYRE Company Descriptions

Pharvaris NASDAQ:PHVS

$22.30 -0.69 (-3.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$22.25 -0.05 (-0.22%)

As of 08/15/2025 04:10 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Arcus Biosciences NYSE:RCUS

$10.39 +0.48 (+4.84%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$10.42 +0.04 (+0.34%)

As of 08/15/2025 07:29 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Spyre Therapeutics NASDAQ:SYRE

$16.95 +0.09 (+0.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$16.50 -0.45 (-2.65%)

As of 08/15/2025 07:36 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Alpha Teknova NASDAQ:TKNO

$4.69 -0.11 (-2.29%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.70 +0.00 (+0.11%)

As of 08/15/2025 04:10 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time